Biogen's stock experienced a positive reaction following the release of its fourth-quarter 2025 earnings. The biotech company reported adjusted earnings per share of $1.99, surpassing the $1.61 consensus estimate. Revenue also exceeded expectations, reaching $2.28 billion, although this represented a 7% year-over-year decline. The shares rose 1.4% on the news.

Driving the positive sentiment, growth products showed continued momentum, increasing 6% year-over-year. Sales of LEQEMBI reached approximately $134 million, up 54% year-over-year, while ZURZUVAE generated approximately $66 million in revenue. For 2026, Biogen anticipates adjusted EPS between $15.25 and $16.25, exceeding analyst consensus, but expects a mid-single digit revenue decline.

This performance indicates the company's focus on key products and financial discipline. The Alzheimer's drug, LEQEMBI, is a key product for Biogen. While the company faces challenges from declining revenue in other areas, the strong outlook for 2026 suggests potential for future growth. Investors will be watching the ongoing performance of Biogen's growth products.

Looking ahead, investors are focused on Biogen's ability to navigate the decline in multiple sclerosis product revenue. The success of LEQEMBI and other growth products will be critical. Further developments in the company's pipeline and strategic decisions will also be important drivers of Biogen's future performance and share price.